Anthony Mancini - 26 May 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Global Commercialization Officer
Issuer ticker: RVMD
Reported as of: 26 May 2026
Net transaction value: -$480,611
SEC form: 4
Accepted by SEC: 28 May 2026, 16:10:48 UTC
Prior SEC filing: 29 Apr 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Anthony Mancini

Key filing fact

Anthony Mancini filed Form 4 for Revolution Medicines, Inc. (RVMD) on 28 May 2026.

Key facts

This page summarizes Anthony Mancini's Form 4 filing for Revolution Medicines, Inc. (RVMD).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 May 2026, 16:10.

Change

Previous filing in this sequence was filed on 29 Apr 2026.
Current net transaction value: -$480,611.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002124509 Primary reporting owner

Mancini Anthony

Relationship: Chief Global Commercialization Officer
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Anthony Mancini
Signature date: 28 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,121
Change %: +5.7%
Price: $33.62^*
Shares after: 57,521
Date: 26 May 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $107,312
Shares: -700
Change %: -1.2%
Price: $153.30
Shares after: 56,821
Date: 26 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

RVMD transaction

Common Stock

Sale

Transaction value: $308,122
Shares: -2,000
Change %: -3.5%
Price: $154.06
Shares after: 54,821
Date: 26 May 2026
Ownership: Direct
Footnotes: F1, F2, F4

RVMD transaction

Common Stock

Sale

Transaction value: $65,177
Shares: -421
Change %: -0.77%
Price: $154.82
Shares after: 54,400
Date: 26 May 2026
Ownership: Direct
Footnotes: F1, F2, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -3,121
Change %: -2.9%
Price: $0.000000^*
Shares after: 106,109
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,121
Exercise price: $33.62
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.

Footnote F2

Includes 54,400 Restricted Stock Units.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $152.64 to $153.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $153.65 to $154.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F5

This transaction was executed in multiple trades at prices ranging from $154.70 to $154.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F6

Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC remarks

Chief Global Commercialization Officer